# CNSP — Cns Pharmaceuticals Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** CNSP  
**Sources:** 20  
**Published:** 2026-10-20  
**Canonical:** https://app.k3vl4r.com/research/deep-research-cnsp-cns-pharmaceuticals-inc-catalysts-narrative-risks-8343

---

## Overview

As of the snapshot date (October 19, 2026 close), CNS Pharmaceuticals (NASDAQ:CNSP) trades at approximately $4.99, with a 52-week range of $1.90–$10.54 and a roughly 45.8% one-year return [[20]](https://finance.yahoo.com/quote/CNSP/). It is a micro-cap biotechnology company in the Healthcare/Biotechnology sector, headquartered in Houston, Texas, pursuing therapies for neurology and oncology [[17]](https://cnspharma.com/ir/). Reported market cap sits at roughly $7.09M–$7.29M depending on the provider and date, though one aggregator lists as low as $1.74M—indicating notable inconsistency in share-count/market-cap data across sources [[15]](https://earningslabs.com/stock/CNSP/earnings)[[20]](https://finance.yahoo.com/quote/CNSP/). The company generates no meaningful revenue and has posted persistent, large quarterly losses [[20]](https://finance.yahoo.com/quote/CNSP/).

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-cnsp-cns-pharmaceuticals-inc-catalysts-narrative-risks-8343 (free to sign up)._
